Immunotherapy produces durable responses in dMMR/MSI-H metastatic colorectal cancer patients with poor performance status

▸ TREATMENT

Patients with dMMR/MSI-H tumors who had poor performance status still achieved durable responses to immunotherapy, expanding treatment options for this vulnerable group. (Clinical Colorectal Cancer)